CyTOF reveals platelet subtype changes predicting the efficacy of combined immunotherapy and targeted therapy in liver cancer
IntroductionImmune checkpoint inhibitors combined with angiogenesis inhibitors are currently the first-line treatment for liver cancer. However, some patients still exhibit poor therapeutic outcomes. Platelets, as a critical component of blood, play a …